Cyclerion Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Several Venrock-affiliated entities and individuals have jointly filed a Schedule 13D, disclosing beneficial ownership of 9.9% of Korsana Biosciences, Inc. common stock following a merger.
NASDAQ
Fairmount Funds Management LLC and its affiliates have disclosed a beneficial ownership of 19.99% in Korsana Biosciences, Inc. following a merger and financing.
NASDAQ
Peter M. Hecht amends Schedule 13D, reporting a beneficial ownership of 910,240 shares of Cyclerion Therapeutics' common stock, representing 19.4% of the class.
NASDAQ
Peter M. Hecht, a significant shareholder, increased his beneficial ownership in Cyclerion Therapeutics, Inc. to 27.9% through a recent private placement of common stock.